Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer.
Kase AM, Gleba J, Miller JL, Miller E, Petit J, Barrett MT, Zhou Y, Parent EE, Cai H, Knight JA, Orme J, Reynolds J, Durham WF, Metz TM, Meurice N, Edenfield B, Alasonyalilar Demirer A, Bilgili A, Hickman PG, Pawlush ML, Marlow L, Wickland DP, Tan W, Copland JA.
Kase AM, et al. Among authors: miller jl.
Mol Cancer Ther. 2024 Mar 6. doi: 10.1158/1535-7163.MCT-23-0296. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38442920